Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human

Linda M. Rorick-Kehn, PhD; Jennifer W. Witcher, PhD; Stephen L. Lowe, PhD; Cledon R. Gonzales, MS; Mary Ann Weller, PhD; Robert L. Bell, MS; John C. Hart, HSD; Anne B. Need, PhD; Jamie H. McKinzie, MS; Michael A. Statnick, PhD; Jeffrey G. Suico, MD; David L. McKinzie, PhD; Sitra Tauscher-Wisniewski, MD; Charles H. Mitch, PhD; Randall R. Stoltz, MD; Conrad J. Wong, PhD

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (Drs Rorick-Kehn, Witcher, Lowe, Gonzales, Bell, Hart, Need, J. McKinzie, Statnick, Suico, D. McKinzie, Tauscher-Wisniewski, Mitch, and Wong); inVentiv Health Clinical, Ann Arbor, Michigan (Dr Weller); Covance Clinical Research Unit, Inc., Evansville, Indiana (Dr Stoltz).

Correspondence: Linda Rorick-Kehn, PhD, Lilly Research Laboratories; Lilly Corporate Center, DC0510; Indianapolis, IN 46285 (rorickkehnlm@lilly.com).

Abstract

Background: Selective kappa opioid receptor antagonism is a promising experimental strategy for the treatment of depression. The kappa opioid receptor antagonist, LY2456302, exhibits ~30-fold higher affinity for kappa opioid receptors over mu opioid receptors, which is the next closest identified pharmacology.

Methods: Here, we determined kappa opioid receptor pharmacological selectivity of LY2456302 by assessing mu opioid receptor antagonism using translational pupillometry in rats and humans.

Results: In rats, morphine-induced mydriasis was completely blocked by the nonselective opioid receptor antagonist naloxone (3 mg/kg, which produced 90% mu opioid receptor occupancy), while 100 and 300 mg/kg LY2456302 (which produced 56% and 87% mu opioid receptor occupancy, respectively) only partially blocked morphine-induced mydriasis. In humans, fentanyl-induced miosis was completely blocked by 50 mg naltrexone, and LY2456302 dose-dependently blocked miosis at 25 and 60 mg (minimal-to-no blockade at 4–10 mg).

Conclusions: We demonstrate, for the first time, the use of translational pupillometry in the context of receptor occupancy to identify a clinical dose of LY2456302 achieving maximal kappa opioid receptor occupancy without evidence of significant mu receptor antagonism.

Keywords: translational biomarker, pupillometry, kappa opioid receptor, dynorphin, LY2456302
Introduction

Although antidepressants are among the most widely prescribed medications, little progress has been made in improving clinical outcomes since the introduction of selective serotonin reuptake inhibitors almost 3 decades ago. Despite being effective therapies for some patients, monoamine-based medications (including selective serotonin reuptake inhibitors, older tricyclic antidepressants, and monoamine-oxidase inhibitors) suffer from delayed onset of antidepressant response and low remission rates (Berton and Nestler, 2006). Because of recent advances in molecular, behavioral, and genetic techniques, efforts are under way to develop novel nonmonoamine-based antidepressants that have the potential to dramatically improve antidepressant treatment response (Berton and Nestler, 2006; Insel, 2012).

Accumulating evidence suggests that selective kappa opioid receptor (KOR) antagonists may be beneficial in the treatment of mood and addictive disorders (Carr et al., 2010; Knoll and Carlezon, 2010; Harrison, 2013; Rorick-Kehn et al., 2014). A recent Phase 2 study demonstrated that ALKS-5461 (buprenorphine + ALKS-33), a formulation resulting in putative kappa antagonism, produced efficacy in treatment-resistant depressed patients with rapid onset of action (Harrison, 2013). In contrast, nonselective opioid antagonists, such as naltrexone, have shown no benefit on mood; rather, they produce dysphoria in certain preclinical models and patient populations (Mendelson et al., 1978; West and Wise, 1988). Preclinical data suggest that potential antidepressant-like effects of opioid antagonists are critically dependent upon KOR selectivity based on neurochemical and electrophysiological evidence that mu- and kappa-opioid systems oppose each other in the brain (Pfeiffer et al., 1986; Spanagel et al., 1992; Margolis et al., 2003). Therefore, it is hypothesized that the predominately mu antagonist component of nonselective opioid antagonists may block the antidepressant effects of KOR antagonism. To test the hypothesis that kappa-selective opioid antagonists may have antidepressant effects, it is essential to identify in human subjects clinical exposures that selectively block KORs without evidence of mu opioid receptor (MOR) antagonism.

Pupilometry is a noninvasive research technique useful for studying the centrally mediated effects of opioids and other drugs in preclinical and clinical paradigms. As a translational biomarker, it is particularly useful for evaluating the potency, efficacy, and duration of action of opioid receptor agonists and antagonists (Knaggs et al., 2004; Lotsch, 2005; Matsoukova et al., 2011). Although MOR agonists produce miosis in humans, rabbits, and dogs, they produce mydriasis in other species, including rodents and cats (Klemfuss et al., 1979). Regardless of whether agonists produce pupillary constriction or dilation in the target species, it is well established that mu-prefering opioid antagonists such as naltrexone and naloxone reliably block the MOR agonist-induced effects in both animals and humans (Klemfuss et al., 1979; Greenwald et al., 1996; Jones et al., 2000). LY2456302 ((S)-3-fluoro-4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide; chemical structure shown in Figure 1b inset) is a structurally novel, selective KOR antagonist with good central penetration and in vivo receptor occupancy, thus confirming that lower doses remain selective for KORs. It has been shown in vitro that LY2456302 produces MOR antagonist activity at doses of 3 mg/kg (corresponding to brain exposures >473 ng/g; see supplemental Table S1). Chemical structures of naloxone and LY2456302 are shown in insets.

Figure 1. Dose-dependent in vivo receptor occupancy at putative mu, kappa, and delta opioid receptors (MOR, KOR, and DOR, respectively) by naloxone and LY2456302 60 minutes after administration. a, Naloxone showed dose- and concentration-dependent occupancy of putative opioid receptors in a manner consistent with its in vitro binding affinity, with MOR and KOR fully saturated at higher doses (3–10 mg/kg). The doses at which 50% of receptors were occupied (ED50) at MOR, KOR, and DOR were 0.49, 0.75, and 3.45 mg/kg, respectively. b, LY2456302 selectively occupied KOR at all doses tested (5–300 mg/kg). At higher doses, MOR antagonist activity was observed (ED50 values = 84.4 and 214.6 mg/kg, respectively). LY2456302 selectively occupies KOR in the rat at doses <100 mg/kg PO. Some engagement of MOR and DOR is evident at 100 and 300 mg/kg (corresponding to brain exposures >473 ng/g; see supplemental Table S1).

Changes in pupil diameter in response to a mu-agonist challenge were measured as a pharmacodynamic (PD) biomarker in both rats and humans. Morphine-induced mydriasis was used in rats and fentanyl-induced miosis was used in humans to assess mu activity. Two fentanyl pupilometry studies were conducted in healthy volunteers, using a low dose of fentanyl (2 μg/kg, intravenously [IV]) that was previously well tolerated and produced robust miosis (Greenwald et al., 1996). In Study A, naltrexone was used to establish the mu-associated effects on miosis. In Study B, LY2456302 was administered to determine its effects on fentanyl-induced miosis.
Preclinical Methods

Animals
Male Sprague-Dawley rats (225–300g; Harlan, Indianapolis, IN) were pair-housed with ad libitum food/water and maintained on a 12-hour–light/–dark cycle. Experiments were conducted in accordance with Guidelines for Care and Use of Laboratory Animals under protocols approved by local Institutional Animal Care and Use Committee.

Study Drugs
LY2456302 (Diaz-Buezo et al., 2009; Mitch et al., 2011) and GR103545 were synthesized at Lilly Research Laboratories (Indianapolis, IN). Naloxone HCl, naltrexone HCl, naltriben methanesulfonate hydrate (naltriben), and morphine sulphate (morphine) were purchased from Sigma Aldrich (St. Louis, MO). LY2456302 was dissolved in sterile water with the drop-wise addition of lactic acid and was orally dosed (3 mL/kg). Naloxone and morphine were dissolved in 0.5% saline and dosed subcutaneously or intraperitoneally, respectively (1 mL/kg). For in vivo receptor occupancy studies, nonlabeled naltrexone (10 µg/kg), naltriben (10 µg/kg), and GR103545 (1.5 µg/kg) were dissolved in saline and dosed IV, as tracers for mu, delta, and kappa receptors, respectively, in a single solution (0.5 mL/kg).

Receptor Occupancy
Occupancy of LY2456302 at opioid receptors was evaluated utilizing an in vivo rat model of central receptor occupancy. Microdoses of nonlabeled naltrexone (10 µg/kg), naltriben (10 µg/kg), and GR103545 (1.5 µg/kg) were used as tracers for MOR (Divin et al., 2009), delta opioid receptors (DORs) (Szekeres and Traynor, 1997), and KOR (Tomasi et al., 2013), respectively. Receptor occupancy was determined 60 minutes after an oral dose of LY2456302 (0, 3, 10, 30, 100, or 300 mg/kg, n = 4/dose) or subcutaneous dose of naloxone (0, 0.1, 0.3, 1, 3, or 10 mg/kg, n = 4/dose) by measuring striatal, thalamic, and cerebellar levels of each tracer by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS; Need et al., 2007). Total binding was represented by tracer levels in striatum (for DOR and KOR) and thalamus (for MOR). The cerebellum, which contains significantly lower densities of MOR, KOR, and DOR, was used for measuring nonspecific binding (Mansour et al., 1994).

Receptor occupancies were calculated using the ratio method described by Wadenberg and colleagues (2000) but substituting the tracer concentrations determined by LC-MS/MS for the radiolabeled tracer levels determined with scintillation spectrometry. The following equation was used:

\[
100 \times \left(1-\frac{\text{ratio}_{\text{t}}}{\text{ratio}_{\text{veh}}}-1\right) = \% \text{ occupancy}
\]

Each “ratio” refers to the ratio of tracer in a target-rich brain area to the tracer level detected in the cerebellum. Ratio, refers to animals treated with test drug and ratio, refers to the average ratio in vehicle-treated animals.

Tissue Preparation/Analysis for In Vivo Receptor Occupancy
Rat brain tissue samples were weighed and placed in conical centrifuge tubes on ice. Four volumes (wt/vol) of acetonitrile containing 0.1% formic acid was added to each tube. The samples were centrifuged after homogenization with an ultrasonic probe. Supernatant was diluted with sterile water in high pressure liquid chromatography (HPLC) injection vials for LC-MS/MS analysis. Tracer analysis was carried out using an Agilent 1200 HPLC (Agilent Technologies, Palo Alto, CA) and an API 3000 mass spectrometer (Applied Biosystems, Foster City, CA). The chromatographic separation employed Zorbax C18 column (Agilent Technologies, Wilmington, DE) gradient from 20% to 90% acetonitrile/water, each with 0.1% formic acid. The total HPLC run time was 3.5 minutes with an additional 2.0 minutes reequilibration time. Detection of small molecule tracers was accomplished by monitoring ion transitions 342.0:324.1, 416.0:398.2, and 414.0:343.0 mass:charge ratio for naltrexone, naltriben, and GR103545, respectively. Standards were prepared by adding known quantities of analyte to brain tissue samples from non-treated rats and processed as described above.

Rat Pupillometry
Rats (n = 10/dose) were acclimated to the test room (30 lux, ambient lighting conditions) for 15 to 30 minutes. Pupil diameter was measured with a Nikon D80 digital camera affixed to a custom-built apparatus with a small vertical partition at a fixed distance (50 cm) from the camera lens. The partition contained a circular opening (1 cm) directly above a metal metric ruler also affixed to the partition. Pupil measurements were determined by briefly holding each rat (1–2 seconds) behind the partition so that the right eye was in the middle of the opening, during which time a digital photo was taken.

After a baseline pupil measurement, rats received 0, 3, 10, 30, 100, or 300 mg/kg LY2456302. A postdose baseline pupil measurement was taken 60 minutes later, after which rats were immediately intraperitoneally dosed with 10 mg/kg morphine. In a separate experiment, rats received 3mg/kg naloxone or vehicle 60 minutes before morphine administration. In each experiment, pupil measurements were taken at 10, 20, 30, 50, 70, and 90 minutes after morphine administration. A single measurement of pupil diameter (in millimeters) was taken at each time point and calculated as percent of baseline by dividing each measurement by the pretreatment baseline measurement (in millimeters). Pupil diameter was measured offline in a blinded manner.

Statistics
Receptor occupancy data were calculated by Prism4 (GraphPad, San Diego, CA) and expressed as mean + standard error of the mean (SEM). Half maximal effective dose (ED_{50}) values were calculated by fitting data to sigmoidal curves using nonlinear regression.

Maximum change in pupil diameter (MaxCPD) was calculated as the ratio of peak pupil diameter for each rat minus pretreatment pupil diameter over mean maximum change of the vehicle group and correlated with rat brain exposure from the receptor occupancy study (GraphPad; San Diego, CA).

For pupillometry, pupil diameter percent of baseline AUEC (area-under-the-effect-curve for pupil diameter in rats, and area-above-the-effect-curve for pupil diameter in humans; refers to the total calculated area of dilation in rats or constriction in humans) was computed for the 90-minute period using the trapezoidal rule. The AUEC values were log-transformed and analyzed using a 1-way analysis of variance model for bioequivalence with treatment of vehicle, LY2456302, and naloxone doses defined as a fixed-effect measure. Primary results were the least-squared mean contrasts (t test) for each LY2456302
dose and naloxone from vehicle. The least-squared mean difference and 90% confidence interval (CI) were back-transformed to obtain the mean ratio and corresponding 90% CI.

**Clinical Methods**

Protocols and informed consent documents for Studies A and B were approved by the local Ethics Review Board. The studies were conducted in accordance with applicable laws and regulations of good clinical practice and ethical principles originating in the Declaration of Helsinki. Adverse events, clinical laboratory values, vital signs (blood pressure, pulse rate), and electrocardiogram results were monitored in both studies.

**Study Drugs**

Naltrexone 50 mg and placebo, supplied from Amide (a division of Mallinckrodt), were each given as 1 tablet in Study A. Fentanyl for Studies A and B was provided in vials as a citrate in water-soluble white crystalline powder from commercial drug product. When diluted, each milliliter of sterile aqueous solution contained a base of 50 μg fentanyl for IV use.

For Study B, LY2456302, provided by Eli Lilly and Company, was supplied as capsules containing 2 or 25 mg LY2456302, with matching placebo capsules. After an overnight fast of ≥8 hours, LY2456302 or placebo capsules were given orally, with water, in the morning. Subjects fasted for at least 4 hours after receiving LY2456302 or placebo.

**Study Design**

Study A was a randomized, subject- and investigator-blind, 3-period crossover study in healthy male subjects, ages 18 to 50 years, with a body mass index (BMI) ≥25 and ≤35 kg/m². Each period consisted of 3 days with ≥7 days washout between periods. An oral dose of naltrexone or placebo was administered on days 1 to 3. On day 3 (third period), approximately 1 hour after naltrexone or placebo administration, subjects were given an IV bolus of fentanyl 2.0 μg/kg or a total dose of 200 μg for subjects weighing ≥100 kg.

Study B was a placebo-controlled, subject-blind, fixed-sequence, adaptive, crossover study with 5 treatment periods that included healthy males and females aged 18 to 65 years, with a BMI ≥18 and ≤32 kg/m². In Period 1, all subjects received a single dose of fentanyl and placebo; in Periods 2 through 5, subjects received a single dose of fentanyl and a single dose of LY2456302 at 4, 10, 25, or 60 mg. Doses of LY2456302 were selected based on the safety and pharmacokinetic (PK) profile from a single ascending dose study in which doses from 2 to 60 mg LY2456302 were administered to healthy volunteers (Low et al., 2014). Fentanyl (2.0 μg/kg or maximum total dose of 200 μg) was administered as a bolus IV injection approximately 2 hours after placebo or LY2456302, at the approximate maximal concentration of drug exposure (Cmax) of LY2456302, as previously determined (Low et al., 2014).

Blood sampling for determination of plasma concentrations of LY2456302 occurred at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 96 hours postdose.

**Bioanalytical Methods**

Study B human plasma samples were analyzed at Advinus Therapeutics (Bangalore, India). Samples were analyzed for LY2456302 using LC-MS/MS. The lower limit of quantification was 0.20 ng/mL, and the upper limit of quantification was 202.70 ng/mL. Interassay accuracy (percent relative error) ranged from −4.55% to 3.19%. Interassay precision (percent relative standard deviation) ranged from 2.10% to 4.76%.

**Pharmacokinetic Analyses**

Study B plasma concentration-time data for LY2456302 were analyzed by noncompartmental methods using WinNonlin Enterprise 5.3. Actual sampling times were used in the estimation of LY2456302 PK parameters with predose times set to zero.

Log-linear trapezoidal rule method was used to estimate area under the plasma concentration vs time curve (AUC). Individual PK parameters estimated were Cmax, time of observed Cmax, AUC from time zero to last quantifiable time point (AUC(0-tlast)), AUC from time zero to infinity (AUC(0-∞)), half-life (t1/2), apparent clearance (CL/F), apparent volume of distribution at steady-state (Vz/F), and apparent volume of distribution (V/F). Mean concentration values were calculated for graphical presentation.

**Pupillometry**

Pupil diameter measurements were made with a validated infrared pupillograph (P2000SA Pupillometer, Procyon, Broomall, PA) using PupilFit software. Under scotopic light conditions (low luminosity – 0.04 lux), 3 to 5 pupil diameter measurements of each subject’s left and right eye were recorded and multiple scans (up to 5) were obtained at every 20-minute nominal time interval. Multiple measurements were aggregated to obtain a single value per nominal time point for each subject. Final mean pupil diameter and median acquisition time values were used in calculations.

For Study A, pupil diameter (millimeters) was measured on day 1 pre-naltrexone or placebo, on day 3 pre-fentanyl, and then at 20-minute intervals for 120 minutes post-fentanyl administration. For Study B, pupil diameter (millimeters) was measured during each study period (for placebo and each dose of LY2456302) at pre-fentanyl administration and at 20-minute intervals for 180 minutes post-fentanyl administration.

Change in pupil diameter (CPD) from baseline over time was calculated to graphically display the time-course of pupil diameter. The apparent nadir of the pupil diameter time-course was observed and termed MaxCPD for each subject/treatment combination. The MaxCPD ratio was calculated as the ratio of treatment to placebo for the MaxCPD endpoint. The pupil diameter AUEC was computed using the trapezoidal rule for the pupil diameter (change from baseline) values.

**Pharmacokinetic/PD Relationship**

The relationship between LY2456302 exposure (AUC(0-∞)) and effects on pupil diameter (MaxCPD and AUEC) was explored to characterize the exposure-response relationship. Modeling of the PK/PD relationships utilized maximum effect (Emax) models in Nonmem (Version 7) and simple linear regression (rat data).

The Emax model utilized for the MaxCPD ratio analyses is shown in Equation 1. The E0 is the baseline ratio and is fixed to a value of 1, and Emax is the estimated maximal effect on MaxCPD. The EC0 is the LY2456302 AUC that produces 50% of the Emax.

**Equation 1:** MaxCPD Ratio = E0 + \( \frac{E_{\text{max}} \times \text{AUC}}{\text{EC}_{0\text{max}}} + \text{AUC} \)

The Emax model utilized for the AUEC analyses is shown in Equation 2. The E0 is the AUEC following fentanyl with a placebo.
dose for LY2456302, and the \( E_{\text{max}} \) is the estimated maximal effect on AUEC. The \( E_{\text{c50}} \) is the LY2456302 AUC that produces 50% of the \( E_{\text{max}} \). Intersubject variability was utilized for the \( E_{\text{c50}} \) parameter.

\[
\text{Equation 2: } \text{AUEC} = E_{\text{c50}} \times \frac{E_{\text{max}} \times \text{AUC}}{E_{\text{c50}} + \text{AUC}}
\]

**Statistics**

Study B data were independently analyzed. Pupil diameter AUEC values were log-transformed and analyzed using a repeated-measures mixed model with treatment of placebo and LY2456302 doses defined as a fixed effect and study period within each subject as a repeated measure. The primary contrast was each LY2456302 dose compared with placebo. The mean difference and CI were back-transformed to obtain the mean ratio and corresponding CI.

A meta-analysis was conducted on the log-transformed AUEC combining data from Study A and Study B. A linear mixed-effects model analyzed the natural log (AUEC) with the random effect of subject and fixed effects of clinical trial (study A and study B) and the treatment effects (placebo-Study A, placebo- Study B, LY2456302 doses and naltrexone 50-mg dose). The primary results were back-transformed to least-squares means with the corresponding 95% mean CI. Pair-wise mean contrasts and corresponding P-values were computed between all LY2456302 doses, naltrexone, and placebo-Study A compared with placebo-Study B.

**Sample Size Statistics**

Assuming an equivalence range of ±20%, a sample size of 10 subjects provided 80% probability that the 90% CI of the overall change in pupil diameter by LY2456302 dose vs placebo would not include 1 (i.e., would detect reversal of mu-agonist-induced effects). Exploratory analysis of Study A revealed that the mean ratio of pupil diameter of naltrexone-placebo under scotopic light conditions during a 3-hour post-fentanyl dose was 1.38, with a within-subject coefficient of variation of 11%. Based on these findings, the sample size of 10 subjects was sufficient for detecting reversal of mu-agonist-induced effects by LY2456302, as identified when the 90% CI of the mean ratio does not include the value of 1.

**Results**

**Rat In Vivo Receptor Occupancy**

Naloxone showed a dose- and concentration-dependent increase in opioid receptor occupancy consistent with its in vitro binding affinity, with MOR and KOP fully saturated at higher doses (3–10 mg/kg; Figure 1; supplementary Table S1). The doses at which 50% of MOR, KOR, and DOR were occupied (ED_{so}) were 0.4, 0.75, and 3.45 mg/kg, respectively (Figure 1a).

In rats, LY2456302 saturated KOR at all doses tested (3–300 mg/kg) and demonstrated dose- and concentration-dependent increases in occupancy of MOR and DOR receptors (Figure 1b), consistent with its in vitro binding affinity (Ki at recombinant human receptors = 0.81, 24.0, and 155 nM for KOR, MOR, and DOR, respectively; Rorick-Kehn et al., 2014). The increasing levels of MOR and DOR occupancy at higher doses (ED_{so} = 84.4 and 214.6 mg/kg, respectively) were driven by proportional increases in plasma and brain exposure of LY2456302 (supplementary Table S1). Results demonstrate that LY2456302 selectively occupies KORs in rat brain with high potency and selectivity in the pharmacological dose range (1–10 mg/kg; Rorick-Kehn et al., 2014), whereas MOR occupancy was observed at LY2456302 doses and exposures ≥10-fold higher than required for preclinical efficacy.

**Clinical Demographics**

Subject demographics are presented in supplementary Table S2. Study A enrolled 15 male subjects (13 completed), and 14 received at least 1 dose of naltrexone; 1 subject received only placebo. Both noncompleters cited personal reasons for early discontinuation. Subjects had a mean age of 32.6 years (range 20–44 years) and mean BMI of 30.2 kg/m² (range 25.9–34.8 kg/m²). Study B enrolled 11 (6 males) subjects with a mean age of 39.8 years (range 21–52 years), mean weight of 72.3 kg (range 49.8–95.7), and mean BMI of 24.6 (range 19.9–27.3). Ten subjects received at least 1 dose of LY2456302, 1 subject received only placebo plus fentanyl. Seven subjects completed Study B; of the 4 subjects who did not, reasons for early discontinuation included subject decision (2), protocol violation (1), and lost to follow-up (1).

**Pharmacokinetics**

In Study B, after single-dose administration, LY2456302 was rapidly absorbed with peak plasma concentrations occurring at 1.5 to 4 hours postdose (Table 1). Pharmacokinetic results were compared with data from a previous single-ascending dose study (Table 1). Following coadministration with fentanyl, there was higher apparent clearance (CL/F) and shorter half-life (t_{1/2}) for the 4-, 10-, and 25-mg doses compared with LY2456302 alone. In contrast, at the 60-mg dose, CL/F was comparable between LY2456302 alone and with fentanyl. Overall, the PK of LY2456302 was comparable when administered alone or with fentanyl. Exposure estimates for each subject were used in the exposure/response pupillometry analyses for pupillometry.

**Safety**

No serious adverse events were reported in Studies A or B. In Study A, the most frequent adverse event (AE) reported during and after fentanyl administration was itching (n = 8). In 3 subjects, nausea led to emesis at approximately 200 μg of fentanyl.

In Study B, a total of 75 AEs were reported by 11 subjects who received ≥1 dose of LY2456302 and/or placebo (supplementary Table S3). The most common AEs considered related to LY2456302 (occurring >1 incidence) were headache (4 events) and nausea (2 events), all mild in severity. After the 25-mg LY2456302 dose, 1 subject experienced severe vomiting and flushing, both short-lived and likely related to fentanyl treatment. Most AEs deemed not related to study drug were consistent with known fentanyl effects. There were no clinically significant values, changes, or trends observed in clinical laboratory data, including neurohormones (cortisol, prolactin, and luteinizing hormone), vital sign values, or electrocardiogram parameters.

**Pupillometry**

Pupil diameter was used as a PD measure to assess the ability of LY2456302 to block morphine-induced mydriasis in rats and fentanyl-induced miosis in humans. As illustrated in Figure 2a, morphine-induced mydriasis in rats was completely blocked by...
Table 1. Noncompartmental Pharmacokinetic Parameters Following a Single Oral Dose of LY2456302 Alone and After Administration of Fentanyl in Healthy Subjects

| LY2456302 dose, mg | Cmax, ng/mL | tmax, h | t1/2, h | AUC(0-∞), ng⋅h/mL | CL/F, L/h | Vz/F, L | Vss/F, L |
|---------------------|-------------|---------|---------|-------------------|-----------|---------|---------|
| 2                   | 4.20 (25)   | 1.50 (1.50–4.00) | 21.3 (62) | 45.6 (46) | 139 (67) | 1070 (52) | 97 (94) |
| 4                   | 11.6 (26)   | 2.01 (1.50–3.00) | 30.0 (7.00–4.00) | 62.2 (42) | 34.8 (22) | 1394 (34) | 120 (94) |
| 10                  | 27.6 (26)   | 1.50 (1.50–3.00) | 35.1 (37) | 89.4 (56) | 91.4 (63) | 1390 (36) | 1130 (64) |
| 25                  | 72.2 (33)   | 2.00 (1.33–3.00) | 42.5 (65) | 170.1 (84) | 374.8 (31) | 1330 (30) | 904 (96) |
| 60                  | 129 (28)    | 2.42 (1.50–3.08) | 22.5 (31) | 268.3 (31) | 41.8 (63) | 1210 (90) | 1130 (64) |
| 4                   | 6.71 (94)   | 3.00 (2.00–4.00) | 25.1 (31) | 136 (39)  | 46.6 (11) | 1270 (27) | 977 (27) |
| 10                  | 23.4 (27)   | 2.02 (1.50–3.00) | 170 (30)  | 1060 (84) | 1610 (94) | 1130 (64) | 904 (96) |
| 25                  | 46.3 (26)   | 2.57 (1.50–3.00) | 21.1 (30) | 1090 (90) | 1520 (39) | 1130 (64) | 904 (96) |
| 60                  | 129 (28)    | 3.00 (1.50–3.00) | 20.0 (15.0–10.00) | 22.5 (31) | 35.2 (30) | 1270 (27) | 977 (27) |

Abbreviations: AUC(0-∞), area under concentration vs time from zero to infinity; Cmax, maximum observed drug concentration; CV, coefficient of variation; tmax, time to maximum observed drug concentration; t1/2, half-life associated with the terminal rate constant (z) in noncompartmental analysis; CL/F, apparent total body clearance of drug calculated after extra-vascular administration; Vz/F, apparent volume of distribution during the terminal phase of elimination; Vss/F, apparent volume of distribution at steady state after extra-vascular administration.

A Data for LY2456302 alone is included from Lowe, Wong, Witcher, Gonzales, Dickinson, Bell, et al. (unpublished data) for comparison.

b LY2456302 plus fentanyl data obtained in Study B. Fentanyl administered 2 h after LY2456302.

c Median (range).
exposure-response relationship for MaxCPD was observed in both rats and humans (Figure 4). The exposure endpoint was brain concentration in rats and plasma AUC in humans. As predicted, the MaxCPD in rats was inversely correlated with LY2456302 brain concentrations (Figure 4a). The exposure-response relationship in healthy humans (Figure 4b) was best described using an Emax (the estimated maximal effect on MaxCPD ratio) model (E0 [the baseline ratio] = 1.00 [fixed]; Emax = –0.918 [36.1%]; EC50 [the AUC that produces 50% of the Emax] = 1270 ng*h/mL [72.8%]). The MaxCPD ratio would approach zero at the maximum effect, based on the model parameters. Based on the model fit, the mean AUC for the 60-mg dose (1700 ng*h/mL) corresponded to a MaxCPD ratio estimate of 0.47, indicating that approximately one-half of the fentanyl-induced miosis was blocked at this dose. The EC50 estimate was 1270 ng*h/mL, suggesting the 60-mg dose produced some moderate blockade of fentanyl-induced miosis, as measured by MaxCPD ratio. Therefore, the maximum effect for the MaxCPD ratio is expected to be achieved at an LY2456302 dose outside the dose range evaluated.

The AUEC exposure-response relationship was evaluated using an Emax model (supplementary Figure S1). This relationship was similar to the dose-response relationship described above for MaxCPD. Similar to MaxCPD (Figure 4), the Emax model parameters suggested that doses of 25 and 60 mg produced some moderate effect, as measured by AUEC, and the maximum effect would be expected at an LY2456302 dose outside the dose range evaluated.

Discussion
We demonstrate here for the first time that the KOR antagonist, LY2456302, produced dose- and concentration-dependent occupancy of MOR in rats at doses and concentrations ≥10-fold
higher than those producing efficacy in preclinical models (Rorick-Kehn et al., 2014). Moreover, we used pupillometry as a translational biomarker in rats and humans to determine doses of LY2456302 necessary to reverse MOR agonist-induced effects, thereby confirming that lower doses remain KOR selective. The higher exposures of LY2456302 required to block MOR-agonist-induced effects on pupil diameter were consistent with its in vitro binding affinity and preclinical in vivo pharmacology (Rorick-Kehn et al., 2014). This finding is noteworthy, because there are currently no KOR-selective antagonists available for clinical evaluation, although the mixed opioid compound buprenorphine, in combination with a mu-prefering antagonist to block its mu partial agonist properties (ALKS-5461), produced significant improvement in depressed patients after 1 week of dosing (Harrison, 2013). Importantly, our findings demonstrate that LY2456302 selectively blocks KOR without evidence of significant MOR antagonism within the dose range of 4 to 10 mg/kg in humans (1–30 mg/kg in rats).

In the rat receptor occupancy study, naloxone produced dose- and concentration-dependent MOR occupancy, with an ED_{50} of 0.49 mg/kg, consistent with reported ED_{50} values for blockade of morphine-induced analgesia in rodents (Vaccarino et al., 1988) as well as efficacy in treating opioid overdose and displacement of t^{11}C-diprenorphine binding in humans (Melichar et al., 2003). In the rat pupillometry study, a 3-mg/kg dose of naloxone that produced 90% MOR occupancy completely blocked morphine-induced mydriasis. The highest doses of LY2456302 tested (100 and 300 mg/kg) produced 56% and 87% MOR occupancy, respectively, and partially blocked morphine-induced mydriasis. The reason for the less robust blockade of morphine-induced mydriasis by LY2456302 is unknown but may be related to the greater overall variability observed in that study.

Our data are consistent with a parametric pupillometry study demonstrating that while morphine dose-dependently increased mydriasis in rats, fluctuations in pupil diameter also dramatically increased in a dose-related manner (Klemfuss et al., 1979). The apparent incomplete blockade may also be related to the relative contributions of MOR and KOR in modulating pupil dynamics. Whereas MOR agonists are well known to regulate pupil diameter, KORs are known to modulate intraocular pressure (Russell and Potter, 2002; Rasmussen et al., 2007). Specifically, MOR agonists reduce intraocular pressure, an effect that is blocked by KOR antagonists (Russell et al., 2000; Russell and Potter, 2002; Rasmussen et al., 2007). Therefore, it is conceivable that LY2456302 effects on intraocular pressure may alter the ability of morphine to produce pupillary changes, such that greater occupancy at MOR is required to overcome alterations in pupil dynamics produced by changes in intraocular pressure. Further studies will be required to determine whether supersaturation of KOR significantly alters mu-agonist-mediated regulation of pupil dynamics.

Consistent with preclinical studies, single oral doses of LY2456302 demonstrated rapid central penetration and potent receptor occupancy in healthy human subjects, with 75% to 100% MOR occupancy at doses of 2 to 25 mg, as measured by displacement of the KOR-selective antagonist positron emission tomography tracer, t^{11}C-LY2795050 (Tauscher et al., 2012). Demonstration of potent KOR occupancy after oral dosing in human subjects provides greater confidence that the clinical hypothesis that KOR-selective antagonists have antidepressant effects will ultimately be tested in Phase 2 studies. It is believed that antidepressant effects of opioid antagonists are critically dependent upon KOR selectivity over other opioid receptor subtypes due to the dysphoria produced by nonselective opioid antagonists, which may attenuate the antidepressant effects of KOR antagonism (Mendelson et al., 1978; West and Wise, 1988). Therefore, we used translational pupillometry techniques to identify clinical doses of LY2456302 that do not exhibit significant antagonism at MOR, which will be used in future efficacy studies.

In our studies in healthy subjects, fentanyl produced robust miosis under scotopic lighting conditions, consistent with previous reports that dim lighting facilitated optimal detection of pupillary changes by opiates (Weinhold and Bigelow, 1993). The fentanyl-induced miosis was completely blocked by 50 mg naltrexone. LY2456302 doses of 25 and 60 mg produced minimal to moderate, but statistically significant, blockade of fentanyl-induced miosis, indicating MOR antagonism. Based on observed MOR activity at 25- to 60-mg doses, a clinical dose of 4 to 10 mg LY2456302 would provide robust and selective KOR occupancy. Importantly, this dose range was well tolerated in healthy subjects (Low et al., 2014). Therefore, the dose- and exposure-response relationships measured here can inform Phase 2 dose selection to avoid doses with notable MOR blockade.
Figure 4. Maximum change in pupil diameter ratio. a, Maximum change in pupil diameter (MaxCPD) ratio in rats (drug:vehicle) is inversely correlated with LY2456302 brain exposure, indicating that, at higher exposures, LY2456302 reduces the magnitude of morphine-induced mydriasis observed. b, MaxCPD ratio in humans (treatment:placebo) is inversely related to LY2456302 exposure and described by the E_{max} (the estimated maximal effect on MaxCPD ratio) model \(E_0\) [the baseline ratio] = 1.00 [fixed], \(E_{max} = -0.918 [36.1\%]\), \(EC_{50}\) [the AUC that produces 50% of the \(E_{max}\)] = 1270 [72.8%].
The PK profile of LY2456302 was well characterized after single doses and compared with similar data from another study (Lowe et al., 2014). Some minor differences in mean PK profiles were noted between LY2456302 alone and when co-administered with fentanyl, most likely because of variability between subjects and periods and not related to drug-drug interactions. Overall, LY2456302 was well tolerated in healthy subjects.

In conclusion, LY2456302 maintains selectivity for KOR within the 4- to 10-mg dose range in healthy volunteers. In conjunction with receptor occupancy, pupillometry represents an excellent translational tool to determine the pharmacological selectivity of novel KOR antagonists, which can be used to test the clinical hypothesis that KOR-selective antagonists may produce antidepressant effects. Here, we provide a model for using a hypothesis-driven approach in developing translational biomarkers that have great impact on guiding dose selection in early clinical trials, based on a clear understanding of target engagement and pharmacological selectivity.

Supplementary Material

For supplementary material accompanying this paper, visit http://www.ijnp.oxfordjournals.org/

Acknowledgments

Studies were sponsored and funded by Eli Lilly and Company, Indianapolis, IN. Portions of this manuscript were written by MaryAnn Weller, a technical writer employed by inVentiv Health Clinical and co-author of the paper. All other authors declare responsibility for the scientific content of the manuscript.

Statement of Interest/Disclosure

L.M.R.-K., J.W.W., S.L.L., C.R.G., R.L.B., J.C.H., A.B.N., J.H.M., M.A.S., J.G.S., D.L.M., S.T.-W., C.H.M., and C.J.W. are employees of, and stockholders in, Eli Lilly and Company at the time the experiments were conducted. M.A.W. is an employee of inVentiv Health Clinical. R.R.S. is an employee of Covance.

References

Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137–151.

Carr GV, Lucki I (2010) Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology (Berlin) 210:295–302.

Díaz-Buezo N, Pedregal-Tercero C, McKinzie D, Mitch C (2009) Kappa selective opioid receptor antagonist. In: US Patent # US20090186873. Issued to Eli Lilly and Company. USA.

Divin MF, Bradbury FA, Carroll FI, Traynor JR (2009) Neutral antagonist activity of naltrizone and 6beta-naltrexol in naive and opioid-dependent C6 cells expressing a mu-opioid receptor. Br J Pharmacol 156:1044–1053.

Greenwald MK, June HL, Stitzer ML, Marco AP (1996) Comparative clinical pharmacology of short-acting mu opioids in drug abusers. J Pharmacol Exp Ther 277:1228–1236.

Harrison C (2013) Opioid receptor blocker shows promise in Phase II depression trial. Nat Rev Drug Discov 12:415.

Insel TR (2012) Next-generation treatments for mental disorders. Sci Transl Med 4:155ps119.

Jones HE, Johnson RE, Fudala PJ, Henningfield JE, Heishman SJ (2000) Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug Alcohol Depend 60:29–37.

Klemfuss H, Tallarida RJ, Adler CH, Adler MW (1979) Morphine-induced mydriasis and fluctuation in the rat: time and dose relationships. J Pharmacol Exp Ther 208:91–95.

Knaggs RD, Crighton IM, Cobby TF, Fletcher AJ, Hobbs GJ (2004) The pupillary effects of intravenous morphine, codeine, and tramadol in volunteers. Anesth Analg 99:108–112.

Knoll AT, Carlezon WA Jr (2010) Dynorphin, stress, and depression. Brain Res 1314C:56–73.

Lotsch J (2005) Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 29:590–593.

Lowe SL, Wong CJ, Wistar KJ, Gonzales CR, Dickinson GL, Bell RL, Rorick-Kehn L, Weller M, Stoltz RR, Royalty J, Tauscher-Wisniewski S (2014) Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol 54:968–978.

Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Aiki H, Watson SJ (1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350:412–438.

Margolis EB, Hjelmstad GO, Bonci A, Fields HL (2003) Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23:9981–9986.

Matouskova O, Slanar O, Chytli L, Perlík F (2011) Pupillometry in healthy volunteers as a biomarker of tramadol efficacy. J Clin Pharm Ther 36:513–517.

Melichar J, Natt DJ, Malizia AL (2003) Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol 459:217–219.

Mendelson JH, Ellingboe J, Keuhnle JC, Mello NK (1978) Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 3:231–236.

Mitch CH, Quimby SJ, Diaz N, Pedregal C, de la Torre MG, Jimenez A, Shi Q, Canada EJ, Kahl SD, Statnick MA, McKinzie DL, Benesh DR, Rash KS, Barth VN (2011) Discovery of aminobenzoylarylamides as kappa opioid receptor selective antagonists: application to preclinical development of a kappa opioid receptor antagonist receptor occupancy tracer. J Med Chem 54:8000–8012.

Mitch CH, McKinzie JH, Mitch CH, Statnick MA, Phebus LA (2007) In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci 81:1389–1396.

Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774–776.

Rasmussen CA, Gabelt BT, Kaufman PL (2007) Aqueous humor dynamics in monkeys in response to the kappa opioid agonist bremazocine. Trans Am Ophthalmol Soc 105:225–238; discussion 238–229.

Rorick-Kehn LM et al. (2014) LY2456302 is a novel, potent, orally-available small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology 77:131–144.

Russell KR, Potter DE (2002) Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-opioid receptors. Exp Eye Res 75:259–270.

Russell KR, Wang DR, Potter DE (2000) Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist. Exp Eye Res 70:675–682.

Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89:2046–2050.
Szekeres PG, Traynor JR (1997) Delta opioid modulation of the binding of guanosine-5’-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther 283:1276–1284.

Tauscher J, Vandenbende F, Witcher J, Ranganathan M, Zheng MQ, Naganawa M, Huang Y, Neumeister A, Carson R (2012) Assessment of brain kappa opioid receptor occupancy after single oral doses of LY2456302 as measured by PET with the radioligand 11C-LY2795050 in healthy subjects. Poster presented 4-Dec-2012 at: Annual Meeting of the American College of Neuropsychopharmacology. http://www.acnp.org/annualmeeting/programbooks.aspx, page 253, #92.

Tomasi G, Nabulsi N, Zheng MQ, Weinheimer D, Ropchan J, Blumberg L, Brown-Proctor C, Ding YS, Carson RE, Huang Y (2013) Determination of in vivo Bmax and Kd for 11C-GR103545, an agonist PET tracer for kappa-opioid receptors: a study in non-human primates. J Nucl Med 54:600–608.

Vaccarino AL, Tasker RA, Melzack R (1988) Systemic administration of naloxone produces analgesia in BALB/c mice in the formalin pain test. Neurosci Lett 84:103–107.

Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422–429.

Weinhold LL, Bigelow GE (1993) Opioid miosis: effects of lighting intensity and monocular and binocular exposure. Drug Alcohol Depend 31:177–181.

West TE, Wise RA (1988) Effects of naltrexone on nucleus accumbens, lateral hypothalamic and ventral tegmental self-stimulation rate-frequency functions. Brain Res 462:126–133.